Filana Therapeutics (NASDAQ: FLNA) adopts new name and FLNA ticker

Rhea-AI Filing Summary

Cassava Sciences, Inc. has changed its legal name to Filana Therapeutics, Inc. effective March 10, 2026, through a Certificate of Amendment filed in Delaware. The board also adopted amended and restated bylaws that update provisions on shareholder and board meetings, advance notice, director terms, special meetings, inspectors of election, and uncertificated shares.

Beginning March 11, 2026, the company’s common stock will trade on the Nasdaq Capital Market under the new ticker symbol FLNA. The corporate website has moved from cassavasciences.com to filanatx.com, where investors can access SEC filings, governance documents, and future Code of Conduct updates.

A press release explains that the new Filana Therapeutics identity aligns with a strategic focus on developing investigational therapies that modulate the filamin A protein to treat central nervous system disorders such as TSC-related epilepsy and other diseases linked to filamin A dysregulation.

false 0001069530 0001069530 2026-03-10 2026-03-10

--12-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 10, 2026

Filana Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-41905	91-1911336
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

6801 N Capital of Texas Highway, Building 1; Suite 300

Austin, Texas 78731

(Address of Principal Executive Offices) (Zip Code)

(512) 501-2444

(Registrant's telephone number, including area code)

Cassava Sciences, Inc.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	SAVA	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.03.  Amendments to Articles of Incorporation or Bylaws.  

 

Effective March 10, 2026, Cassava Sciences, Inc. changed its legal name (the “Name Change”) to Filana Therapeutics, Inc. (the “Company”). The Company filed with the Secretary of State of the State of Delaware an amendment to its Restated Certificate of Incorporation of Cassava Sciences, Inc. (the “Certificate of Amendment”) to effect the Name Change as of March 10, 2026. The Company’s board of directors also adopted amended and restated By-Laws of the Company (“Amended By-Laws”) reflecting the Name Change, effective as of March 10, 2026. In addition to the Name Change, the Amended By-laws also clarify and modernize certain provisions relating to stockholder and board meetings, advance notice requirements, director terms, special meetings, inspectors of election, and uncertificated shares. There were no changes to the Restated Certificate of Incorporation other than the Name Change.

Copies of the Certificate of Amendment, as filed with the Secretary of State of the State of Delaware, and the Amended By-Laws, are attached hereto as Exhibit 3.1 and Exhibit 3.2, respectively, and are incorporated herein by reference.

 

Effective March 11, 2026, shares of the Company’s common stock, par value $0.001 per share, will trade on the Nasdaq Stock Market under the ticker symbol “FLNA”.

In connection with the Name Change, the Company has changed its existing corporate website address from  www.cassavasciences.com to www.filanatx.com (the “New Website”). The Company’s investor relations information, including press releases and links to the Company’s SEC filings, will now be found on the New Website. The Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the Company’s corporate governance documents, including the charters of the committees of the Company’s board of directors, Corporate Governance Principles and Code of Conduct, are available on the New Website. Any amendment to or waivers of the Code of Conduct will be disclosed on the New Website. The website references herein are inactive textual references and the contents of such websites are not incorporated by reference in this Current Report on Form 8-K.

Item 7.01.  Regulation FD Disclosure.

A copy of the Company’s press release announcing the Name Change is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific references in such a filing.

Forward Looking Statements

This Form 8-K contains certain statements concerning the Company that are considered forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Forward-looking statements include terms, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and “would” or the negatives of these terms or other comparable terminology. The forward-looking statements are based on the Company’s beliefs, assumptions and expectations of its future performance, taking into account all information currently available to the Company. Forward-looking statements involve risks and uncertainties and the Company’s actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. The Company cannot assure that it will realize the results or developments that the Company expects or anticipates or, even if substantially realized, that they will result in the consequences or affect the Company or its operations in the way it expects. The forward-looking statements included in this Current Report on Form 8-K are made only as of the date hereof.  The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Item 9.01.  Financial Statements and Exhibits.

Exhibit No.		Description
3.1		Certificate of Amendment, as filed with the Secretary of State of the State of Delaware, effective March 10, 2026
3.2		Amended and Restated By-Laws of Filana Therapeutics, Inc., dated as of March 10, 2026
99.1		Press Release issued by Filana Therapeutics, Inc. on March 10, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Filana Therapeutics, Inc.
	a Delaware corporation
Date: March 10, 2026	By:	/s/ Eric J. Schoen
		Eric J. Schoen
		Chief Financial Officer

Exhibit 99.1

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy

Filana Therapeutics to begin trading under “FLNA” effective March 11, 2026

AUSTIN, TX, March 10, 2026 (GLOBENEWSWIRE) – Cassava Sciences, Inc. (NASDAQ: SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. (“Filana Therapeutics”, or the “Company”). The new name and corporate brand reflect the Company’s strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A.

The Company will begin trading under the new ticker symbol “FLNA” on the Nasdaq Capital Market at the open of the market on March 11, 2026.

“The launch of Filana Therapeutics represents a new beginning for our Company. Growing evidence suggests that filamin A is an important regulator of neuronal development and that modulating filamin A may provide a new approach to treating CNS disorders such as TSC-related epilepsy. Centering our identity on filamin A reflects our dedication to rigorous scientific discovery and to bringing new treatment options to patients and their families,” said Rick Barry, President and Chief Executive Officer of Filana Therapeutics.

The updated corporate website is available at: https://www.filanatx.com.

About TSC and TSC-related Epilepsy

TSC is a rare genetic disorder resulting from a mutation in the TSC1 or TSC2 gene. This affects the mechanistic target of rapamycin (mTOR) pathway and can cause tumors to grow in multiple organs¹. Epilepsy is the most common health issue affecting the TSC community, with 80% to 90% of TSC patients experiencing seizures^1. TSC-related epilepsy affects approximately 45,000 people in the U.S.² Most patients start having seizures within their first year of life³. Even with multiple approved treatments, more than 60% of TSC patients remain refractory to antiepileptic therapy⁴.

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc. (NASDAQ: FLNA), is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A.

For more information, please visit: https://www.filanatx.com

References:

1.	Crino P, Nathanson K, Petri Henske, E. The Tuberous Sclerosis Complex. N Engl J Med. (2006) 355 (13):1345-56. DOI: 10.1056/NEJMra055323
2.	Zhang L, Huang T, Teaw S, Nguyen LH, Hsieh LS, Wong X, Burns LH, Bordey A. Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations. Science Translational Medicine. (2020) 12(531):eaay0289. DOI: 10.1126/scitranslmed.aay0289
3.	https://www.tscalliance.org/understanding-tsc/what-is-tsc/
4.	Chu-Shore, C. J., Major, P., Camposano, S., Muzykewicz, D., & Thiele, E. A. (2010). The natural history of epilepsy in tuberous sclerosis complex. Epilepsia, 51(7), 1236–1241. https://doi.org/10.1111/j.1528-1167.2009.02474.x

For More Information Contact:

Investors
Sandya von der Weid
svonderweid@lifesciadvisors.com

Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@filanatx.com
IR@filanatx.com

Cautionary Note Regarding Forward-Looking Statements:

This news release contains forward-looking statements that may include but are not limited to statements regarding the Company’s new mission, strategy and brand, and the Company’s ongoing development program in TSC-related epilepsy. Forward-looking statements may be identified by words such as “anticipate”, “before”, “believe”, “could”, “expect”, “forecast”, “intend”, “may”, “pending”, “plan”, “possible”, “potential”, “prepares for”, “will”, and other words and terms of similar meaning.

Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks inherent in drug discovery and development or specific to Filana Therapeutics, Inc., as described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10‑Q for the period ended September 30, 2025, and subsequent reports periodically filed and to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at www.sec.gov.

All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.

Our clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.

We are in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and any other SEC filings in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.

FAQ

What corporate change did Cassava Sciences (SAVA) announce in this 8-K?

The company changed its legal name from Cassava Sciences, Inc. to Filana Therapeutics, Inc. effective March 10, 2026. This was implemented via a Certificate of Amendment in Delaware and accompanied by amended and restated bylaws reflecting the new name.

What is the new stock ticker and when will Filana Therapeutics start trading under it?

Filana Therapeutics will trade under the new Nasdaq ticker symbol FLNA starting March 11, 2026. The shares remain common stock with a $0.001 par value, and the listing continues on the Nasdaq Capital Market following the rebranding.

How did Filana Therapeutics update its bylaws in connection with the name change?

The company adopted amended and restated bylaws that incorporate the new name and modernize governance provisions. Updates address stockholder and board meetings, advance notice requirements, director terms, special meetings, inspectors of election, and uncertificated shares, with no other changes to the Restated Certificate of Incorporation.

What is Filana Therapeutics’ updated corporate website for investor information?

Filana Therapeutics’ new corporate website is www.filanatx.com. Investor relations materials, including press releases, SEC filings, annual and quarterly reports, and corporate governance documents such as committee charters and the Code of Conduct, are now available through this updated site.

What therapeutic focus does Filana Therapeutics highlight after the rebranding?

Filana Therapeutics emphasizes developing novel investigational therapies that modulate the filamin A protein. The strategy targets central nervous system disorders, notably tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A.

Does this filing include any financial statements or major transactions for Filana Therapeutics?

This disclosure centers on the corporate rebranding, ticker change, and bylaw updates, not on financial results or major business transactions. It attaches the Certificate of Amendment, amended bylaws, and a press release as exhibits for reference.

Filing Exhibits & Attachments

7 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 16.2 KB

Other Documents

• EX-3.1 EXHIBIT 3.1 8.9 KB
• EX-3.2 EXHIBIT 3.2 124.1 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 12.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 12.2 KB